Characteristics of COVID-19 Therapy Based on Disease Severity at Siloam Kebon Jeruk Hospital
DOI:
https://doi.org/10.19166/med.v14i1.9233Keywords:
COVID-19, Severity, Antiviral, Anti-inflammatory, AnticoagulantAbstract
Introduction : COVID-19 is an infectious disease that can cause acute respiratory syndrome by droplet transmission. Along with the very fast spread of the virus which occurs in almost all countries, it is necessary to have therapies that can reduce the morbidity and mortality of patients infected with COVID-19. Various factors affect the administration of therapy so a management guideline is needed for medical personnel so that the administration of therapy can be consistent and efficient in accordance with scientific evidence. This study aims to determine the characteristics and therapeutic options of COVID-19 patients based on the severity of the disease so it can be an evaluation for policymakers and health workers in providing COVID-19 therapy.
Methods : This type of research is descriptive, and the research design is cross-sectional with a total population sampling. The study was conducted at Siloam Kebon Jeruk Hospital with a total of 135 respondents from secondary medical record data.
Results : The observed data include the characteristics of the respondents and the therapies for COVID-19 patients, which consist of antiviral, anti-inflammatory, and anticoagulant treatments. Based on the collected data, COVID-19 patients were predominantly male (55.6%) with an average age of 55 years. Many patients presented with moderate severity without requiring oxygen (34.1%) and were classified as having referred outcomes (47.4%). Antiviral therapy using favipiravir was predominantly administered to patients with mild to moderate severity, while remdesivir was mostly given to those with moderate to severe severity. Corticosteroids, such as dexamethasone and methylprednisolone, were the preferred choice for anti-inflammatory therapy (72.2%). Heparin was the most commonly used anticoagulant therapy across all severity levels, and antibiotics were administered to the majority of patients infected with COVID-19 (73.3%).
Conclusions : Evaluation of the low rate of use of corticosteroids and anticoagulants in COVID-19 patients is needed.
References
1. Organização Mundial da Saúde. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. 2024. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
2. Komite Penanganan Covid-19 dan Pemulihan Ekonomi Nasional. Peta Sebaran. Peta Sebaran. 2021. Available from: https://covid19.go.id/peta-sebaran
3. Narazio B. Pneumonia and coronavirus: does everyone with COVID-19 get pneumonia.
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507–13. https://doi.org/10.1016/s0140-6736(20)30211-7
5. Mesquita R, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira T, Campos Alcântara R, Monteiro Arnozo G, et al. Clinical manifestations of COVID-19 in the general population: systematic review. Wien Klin Wochenschr. 2021 Apr;133(7–8):377–82. https://doi.org/10.1007/s00508-020-01760-4
6. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020 Aug;20(8):e192–7. https://doi.org/10.1016/s1473-3099(20)30483-7
7. Varkey B. Principles of Clinical Ethics and Their Application to Practice. Med Princ Pract. 2021;30(1):17–28. https://doi.org/10.1159/000509119
8. Hajjaj FM, Salek MS, Basra MKA, Finlay AY. Non-clinical influences on clinical decision-making: a major challenge to evidence-based practice. J R Soc Med. 2010 May;103(5):178–87. https://doi.org/10.1258/jrsm.2010.100104
9. Brichko L, Mitra B, Cameron P. When guidelines guide us to harm. Emerg Med Australas. 2018 Dec;30(6):740–2. https://doi.org/10.1111/1742-6723.13189
10. Khaerunnisa R, Rumana NA, Yulia N, Fannya P. Gambaran Karakteristik Pasien Covid-19 di Rumah Sakit Mekar Sari Bekasi Tahun 2020-2021. JurnalMIKI. 2022 Mar 2;10(1):72. https://doi.org/10.33560/jmiki.v10i1.390
11. Arifin ZA, Melati Inayati Albayani, Baiq Ruli Fatmawati, Marthilda Suprayitna. Identifikasi Karakteristik Penderita Covid-19 di Provinsi Nusa Tenggara Barat. Jurnal CARING. 2021 Mar 3;4(2):1–6.
12. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2021. Available from: https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)
13. Pratiwi ADE, Adhityasmara D. Gambaran Penggunaan Antikoagulan Pada Pasien Covid-19 Di Salah Satu Rumah Sakit Rujukan Covid-19 Di Kota Semarang. Sebatik. 2021 Dec 1;25(2):442–8. https://doi.org/10.46984/sebatik.v25i2.1619
14. Kusumawardani LA, Maria N, Fanani YN. Potential drug interactions analysis of COVID-19 patients at a hospital in West Java. JIF. 2021 Dec 28;17(2):182–97. https://doi.org/10.20885/jif.vol17.iss2.art8
15. Pepitasari BD, Anggraini TD. Gambaran Tatalaksana Terapi Pada Pasien COVID-19 Terkonfirmasi di Rumah Sakit X Kota Surakarta Periode Maret – Desember 2020. Indonesian j on Med Sci [Internet]. 2021 Jul 15 [cited 2024 Dec 11];8(2). Available from: http://ejournal.poltekkesbhaktimulia.ac.id/index.php/ijms/article/view/321
16. Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021 May 27;21(1):489. https://doi.org/10.1186/s12879-021-06164-x
17. Deng ZM, Dai FF, Yuan MQ, Yang DY, Zheng YJ, Cheng YX. Advances in molecular mechanisms of pelvic organ prolapse (Review). Exp Ther Med. 2021 Sep;22(3):1009. https://doi.org/10.3892/etm.2021.10442
18. Almoosa Z, Saad M, Qara S, Mustafa M, Mansour A, Alshab D, et al. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study. J Infect Public Health. 2021 Sep;14(9):1247–53. https://doi.org/10.1016/j.jiph.2021.08.022
19. Rahmandani A, Sarnianto P, Anggriani Y, Dermawan Purba F. Analisis Efektivitas Biaya Penggunaan Obat Antivirus Oseltamivir dan Favipiravir pada Pasien Covid-19 Derajat Sedang di Rumah Sakit Sentra Medika Cisalak Depok. Maj Farmasetika. 2021 Dec 30;6(1):133. https://doi.org/10.24198/mfarmasetika.v6i0.36667
20. Tan Q, Duan L, Ma Y, Wu F, Huang Q, Mao K, et al. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. Bioorg Chem. 2020 Nov;104:104257. https://doi.org/10.1016/j.bioorg.2020.104257
21. Guideline Development Group. Therapeutics and COVID-19: living guideline [Internet]. 2021 [cited 2021 Apr 9]. Available from: who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.2
22. Mozaffari E, Chandak A, Chima-Melton C, Kalil AC, Jiang H, Lee E, et al. Remdesivir is Associated with Reduced Mortality in Patients Hospitalized for COVID-19 Not Requiring Supplemental Oxygen. Open Forum Infectious Diseases. 2024 Jun 3;11(6):ofae202. https://doi.org/10.1093/ofid/ofae202
23. Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, et al. Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. The Journal of Infectious Diseases. 2020 Apr 27;221(10):1688–98. https://doi.org/10.1093/infdis/jiz656
24. Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020 Oct 29;383(18):1757–66. https://doi.org/10.1056/nejmcp2009249
25. Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020 May;212(9):416–20. https://doi.org/10.5694/mja2.50577
26. Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021 Dec;21(1):337. https://doi.org/10.1186/s12879-021-06045-3
27. Rana MA, Hashmi M, Qayyum A, Pervaiz R, Saleem M, Munir MF, et al. Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving PaO2/FiO2 Ratio Among COVID-19 Patients. Cureus. 2020 Oct 12;12(10):e10918. https://doi.org/10.7759/cureus.10918
28. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020 Dec;29:100639. https://doi.org/10.1016/j.eclinm.2020.100639
29. Cattaneo M, Bertinato EM, Birocchi S, Brizio C, Malavolta D, Manzoni M, et al. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? Thromb Haemost. 2020 Aug;120(8):1230–2. https://doi.org/10.1055/s-0040-1712097
30. Mohtadi N, Ghaysouri A, Shirazi S, Sara Ansari null, Shafiee E, Bastani E, et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series. Virology. 2020 Sep;548:1–5. https://doi.org/10.1016/j.virol.2020.05.006
31. Moradimajd P, Samaee H, Sedigh-Maroufi S, Kourosh-Aami M, Mohsenzadagan M. Administration of intravenous immunoglobulin in the treatment of COVID-19: A review of available evidence. J Med Virol. 2021 May;93(5):2675–82. https://doi.org/10.1002/jmv.26727
32. Yang P, Wang J, Zheng R, Tan R, Li X, Liu X, et al. Convalescent plasma may not be an effective treatment for severe and critically ill covid-19 patients: A Systematic Review & Meta-Analysis of Randomized Controlled Trials. Heart Lung. 2022;53:51–60. https://doi.org/10.1016/j.hrtlng.2022.01.019
33. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 Dec;26(12):1622–9. https://doi.org/10.1016/j.cmi.2020.07.016
34. Karataş M, Yaşar-Duman M, Tünger A, Çilli F, Aydemir Ş, Özenci V. Secondary bacterial infections and antimicrobial resistance in COVID-19: comparative evaluation of pre-pandemic and pandemic-era, a retrospective single center study. Ann Clin Microbiol Antimicrob. 2021 Aug 5;20(1):51. https://doi.org/10.1186/s12941-021-00454-7
35. Hendaus MA, Jomha FA. Covid-19 induced superimposed bacterial infection. J Biomol Struct Dyn. 2021 Jul;39(11):4185–91. https://doi.org/10.1080/07391102.2020.1772110
36. Sujana KS, Maulida M. Efektivitas N-Acetylsistein pada Pasien COVID-19. Cermin Dunia Kedokteran. 2021 Jul 1;48(7):416–8. https://doi.org/10.55175/cdk.v48i7.99
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Teddy Tjahyanto, Velma Herwanto
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.
